Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic and Dose Response Relationships Observed in the Study “a Phase 1, Open- Label Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTX-100 in Patients with Advanced and Relapsed/Refractory T Cell Lymphoma”

Terrence Chew, Mariam Mansour, Luis Fernando MALAVER ORTEGA, Upaly Bahadure, Costas K. Yannakou, Steven Lee Yatomi-Clarke, H. Miles Prince

Blood (2024) 144 (Supplement 1): 6414.

https://doi.org/10.1182/blood-2024-207750

Published: 2024

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin

Blood (2024) 144 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2024-208192

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study

Emmanuel Bachy, Tae Min Kim, Shang-Ju Wu, Jan Walewski, Jingxian Cai, Nickolas Sophos, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince

Blood (2024) 144 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2024-200150

Published: 2024

Journal Articles

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Mark N Sorial, Sean M McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. J. Fernandez Turizo, Caroline MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra W Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven Horwitz, Mwanasha H. Merrill, Eric D. Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie G Ford, Martina Manni, Monica Civallero, Tetiana Skrypets, Massimo Federico, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2024) 144 (Supplement 1): 465.

https://doi.org/10.1182/blood-2024-201874

Published: 2024

Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 460.

https://doi.org/10.1182/blood-2024-200992

Published: 2024

Journal Articles

Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study

Sabarish Ayyappan, H. Miles Prince, Cecilia Carpio, Isidro Jarque, Srikanth Ambati, Chinjune Lin, Hesham Mohamed, Giovanni Antico, C. Akunna Otele, Jan Walewski

Blood (2024) 144 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2024-199477

Published: 2024

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Blood (2023) 142 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2023-180743

Published: 2023

Journal Articles

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients with Advanced Malignancies

Terrence Chew, Costas K. Yannakou, Vinod Ganju, Steven Grant, Said Sebti, H. Miles Prince

Blood (2023) 142 (Supplement 1): 1705.

https://doi.org/10.1182/blood-2023-179411

Published: 2023

Journal Articles

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Joaquin Martinez-Lopez, Guenther Koehne, Paula Rodriguez Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T Sullivan, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2023-182130

Published: 2023

Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 436.

https://doi.org/10.1182/blood-2023-179818

Published: 2023

Journal Articles

Blocked addiction to IL-15 for treating T-LGLL

H. Miles Prince

Blood (2023) 142 (15): 1258–1260.

https://doi.org/10.1182/blood.2023021476

Published: 2023

Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Blood (2022) 140 (Supplement 1): 1070–1071.

https://doi.org/10.1182/blood-2022-158406

Published: 2022

Journal Articles

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Blood (2022) 140 (Supplement 1): 7317–7319.

https://doi.org/10.1182/blood-2022-157302

Published: 2022

Journal Articles

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Nobuhiro Tsukada, Kazutaka Sunami, Pierre Bories, Sumit Madan, Dorothee Semiond, Disa Yu, Sandrine Macé, Florence Suzan, Philippe Moreau

Blood (2022) 140 (Supplement 1): 4412–4414.

https://doi.org/10.1182/blood-2022-166840

Published: 2022

Journal Articles

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Paul G. Richardson, Aurore Perrot, Jesús San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Laure Malinge, Franck Dubin, Mony Morisse, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 608–610.

https://doi.org/10.1182/blood-2022-159710

Published: 2022

Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Blood (2022) 140 (Supplement 1): 391–393.

https://doi.org/10.1182/blood-2022-162440

Published: 2022

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

NARROW

Pharmacokinetic and Dose Response Relationships Observed in the Study “a Phase 1, Open- Label Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTX-100 in Patients with Advanced and Relapsed/Refractory T Cell Lymphoma”

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients with Advanced Malignancies

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blocked addiction to IL-15 for treating T-LGLL

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only